Learning from case law: Case C-118/24 AG opinion on whether a drug product licensed via the Article 10(i) of Directive 2001/83 abridged licensing procedure can ever be recognised as a generic of a biologic medicinal product

Last updated: 16 June 2026 To view updates, click on the ‘+’ sign below. This post is an attempt to provide salient information on Case C-118/24 concerning EG Labo Laboratoires Eurogenerics SAS and Theramex France SAS vs the French Regulatory…

Read MoreLearning from case law: Case C-118/24 AG opinion on whether a drug product licensed via the Article 10(i) of Directive 2001/83 abridged licensing procedure can ever be recognised as a generic of a biologic medicinal product

Learning from Case Law: Case C‑456/24, AG opinion on whether or not a Supplementary Protection certificate (SPC) can be granted for an excipient

This post is an attempt to provide salient information on Case C-456/24 which concerns Halozyme Inc. vs the Supreme Administrative Court, Czech Republic. Specifically, it concerns the events leading up to the CJEU getting involved in the case as well…

Read MoreLearning from Case Law: Case C‑456/24, AG opinion on whether or not a Supplementary Protection certificate (SPC) can be granted for an excipient

EMA launches pilot to support development of ‘breakthrough’ medical devices in the EU

Last updated: 6 May 2026 To view updates, click on the ‘+’ sign below. The EMA has launched a pilot programme to support the development of breakthrough medical devices in the European Union (EU). EMA launched this pilot on 28 April 2026.…

Read MoreEMA launches pilot to support development of ‘breakthrough’ medical devices in the EU

The registration obligation for MD and IVD devices in Swissdamed

Medical Devices (MD) registration When will the registration of Medical devices and procedure packs in Swissdamed become mandatory and replace the notification obligation and is there a transition period? The registration of devices, systems, and procedure packs according to Art.…

Read MoreThe registration obligation for MD and IVD devices in Swissdamed

MHRA to help developers to make greater use of New Approach Methodologies in order to phase out animal testing

What action(s) is the MHRA taking in order to phase out animal testing? The MHRA has taken decisive action to phase out animal testing by helping developers to make greater use of New Approach Methodologies (NAMs). By offering early review…

Read MoreMHRA to help developers to make greater use of New Approach Methodologies in order to phase out animal testing